<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>59</volume><submitter>Duan H</submitter><pubmed_abstract>Colorectal cancer (CRC) is among top most common cancers with high mortality rate and major health issue yet to resolve across the globe. miR-23b is an oncogene in many cancers including CRC. The route of involvement of miR-23b in the regulation of CRC is still unclear. Study explored bioregulatory mechanism of miR-23b against CRC involving in vitro and animal model experimentation via experimentation involving ki67 immunohistochemistry, CCK8, EDU, and Transwell cell migration. The bioinformatic studies were employed to predict miR-23b target tumor suppressor PTPRG while the luciferase reporter gene assay was used to find the binding capabilities of miR-23b to the 3'-UTR of PTPRG. The changes in the expression of miR-23b were found in three CRC cell lines including SW480, HT29, and Caco2, </pubmed_abstract><journal>Translational oncology</journal><pagination>102447</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC12240168</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>miR-23b is a negative regulator of tumor suppressing PTPRG in colorectal cancer.</pubmed_title><pmcid>PMC12240168</pmcid><pubmed_authors>Yang J</pubmed_authors><pubmed_authors>He C</pubmed_authors><pubmed_authors>Wang T</pubmed_authors><pubmed_authors>Li F</pubmed_authors><pubmed_authors>Hu H</pubmed_authors><pubmed_authors>Zhai K</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Khan GJ</pubmed_authors><pubmed_authors>Duan H</pubmed_authors><pubmed_authors>Jia J</pubmed_authors><pubmed_authors>Wang L</pubmed_authors></additional><is_claimable>false</is_claimable><name>miR-23b is a negative regulator of tumor suppressing PTPRG in colorectal cancer.</name><description>Colorectal cancer (CRC) is among top most common cancers with high mortality rate and major health issue yet to resolve across the globe. miR-23b is an oncogene in many cancers including CRC. The route of involvement of miR-23b in the regulation of CRC is still unclear. Study explored bioregulatory mechanism of miR-23b against CRC involving in vitro and animal model experimentation via experimentation involving ki67 immunohistochemistry, CCK8, EDU, and Transwell cell migration. The bioinformatic studies were employed to predict miR-23b target tumor suppressor PTPRG while the luciferase reporter gene assay was used to find the binding capabilities of miR-23b to the 3'-UTR of PTPRG. The changes in the expression of miR-23b were found in three CRC cell lines including SW480, HT29, and Caco2, </description><dates><release>2025-01-01T00:00:00Z</release><publication>2025 Sep</publication><modification>2026-03-15T14:00:58.242Z</modification><creation>2025-08-13T03:04:29.089Z</creation></dates><accession>S-EPMC12240168</accession><cross_references><pubmed>40561798</pubmed><doi>10.1016/j.tranon.2025.102447</doi></cross_references></HashMap>